Published in Ann Intern Med on December 01, 1981
Prognosis after myocardial infarction: results of 15 year follow up. Br Med J (Clin Res Ed) (1984) 1.17
Transport-dependent anoxic cell injury in the isolated perfused rat kidney. Am J Pathol (1984) 0.86
Intravenous short-term infusion of streptokinase in acute myocardial infarction. Tex Heart Inst J (1984) 0.75
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Increased particulate air pollution and the triggering of myocardial infarction. Circulation (2001) 6.94
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med (1996) 6.92
Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med (1993) 6.72
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 5.15
Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med (1985) 5.09
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. Circulation (1995) 5.06
TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41
Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33
Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest (1965) 4.23
Myocardial reperfusion: a double-edged sword? J Clin Invest (1985) 4.12
Circadian variation in the frequency of sudden cardiac death. Circulation (1987) 3.98
A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med (1980) 3.98
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation (1968) 3.82
Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol (1971) 3.68
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Morning increase in onset of ischemic stroke. Stroke (1989) 3.52
Aortic stenosis. Circulation (1968) 3.49
Triggering myocardial infarction by marijuana. Circulation (2001) 3.36
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med (1971) 3.24
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13
Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 3.07
Triggering of myocardial infarction by cocaine. Circulation (1999) 3.06
Mechanism of action of calcium-channel-blocking agents. N Engl J Med (1982) 2.99
Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93
Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med (1987) 2.83
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 2.78
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64
Cholecystokinin and its COOH-terminal octapeptide in the pig brain. Proc Natl Acad Sci U S A (1977) 2.62
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest (1967) 2.51
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47
Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol (1991) 2.40
Unstable angina: an etiologic approach to management. Circulation (1998) 2.31
The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation (1965) 2.30
Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol (1968) 2.29
Coronary-artery surgery at the crossroads. N Engl J Med (1977) 2.28
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J (2001) 2.28
Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol (1987) 2.27
Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Coronary-artery spasm. N Engl J Med (1978) 2.20
Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med (1980) 2.20
Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol (1986) 2.20
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med (1980) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patients. Am J Cardiol (1983) 2.18
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation (1999) 2.16
Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole. Circulation (1971) 2.15
Velocity of contraction as a determinant of myocardial oxygen consumption. Am J Physiol (1965) 2.11
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med (1980) 2.08
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA (2001) 2.07
Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med (1978) 2.03
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation (2000) 2.01
Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol (1987) 2.01
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA (1996) 1.99
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J (2002) 1.98
Modification of myocardial infarction size after coronary occlusion. Ann Intern Med (1973) 1.98
The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation (1966) 1.97
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med (1981) 1.97
Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation (1998) 1.96
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol (1998) 1.96
Digoxin therapy and mortality after myocardial infarction. Experience in the MILIS Study. N Engl J Med (1986) 1.96
Reflex increase in coronary vascular resistance in patients with ischemic heart disease. N Engl J Med (1976) 1.92
Control of myocardial oxygen consumption: relative influence of contractile state and tension development. J Clin Invest (1968) 1.90
The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation (1987) 1.89
Can medical schools remain the optimal site for the conduct of clinical investigation? Presidential address before the 67th annual meeting of the American Society for Clinical Investigation, Atlantic City, New Jersey, 5 May 1975. J Clin Invest (1975) 1.87
Rapid sequential visualization of the heart and great vessels in man using the wide-field anger scintillation camera. Radioisotope-angiography following the injection of technetium-99m. Circulation (1969) 1.86
Applying the open artery theory: use of predictive survival markers. Eur Heart J (1998) 1.85
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83
Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med (1966) 1.83